Methylation‐Based Analysis of Circulating DNA for Breast Tumor Screening

Rykova, Elena Y.; Tsvetovskaya, Galina A.; Sergeeva, Galina I.; Vlassov, Valentin V.; Laktionov, Pavel P.

doi:10.1196/annals.1448.021

Cited by 11 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The promising way to increase the sensitivity of the cirDNA-based assay was recently developed by group of Laktionov, who performed MSP using cirDNA extracted from plasma and eluates from the surface of blood cells [48,147]. The authors reported the presence of tumor-associated methylated genes in the cell-surface-bound DNA (csbDNA).…”

Section: Cirdna Methylation-based Assay Developmentmentioning

confidence: 98%

“…The authors reported the presence of tumor-associated methylated genes in the cell-surface-bound DNA (csbDNA). Moreover, tumorrelated methylated forms of three genes (RAR 2, RASSF1A and HIC-1) were much more frequently evaluated in the cell-surface-bound circulating DNA compared with cell-free plasma cirDNA in breast tumorbearing patients [147]. The sensitivity of gastric cancer detection by MSP assays was increased significantly when cirDNA, extracted from plasma, and csbDNA were used as the template for MSP [48].…”

Section: Cirdna Methylation-based Assay Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.

show abstract

Section: Cirdna Methylation-based Assay Developmentmentioning

confidence: 98%

Section: Cirdna Methylation-based Assay Developmentmentioning

confidence: 99%

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

show abstract

“…Aberrant methylation of CpG islands within the promoters and 5’-end regulatory regions of genes is increasingly being recognized as a frequent epigenetic modification and has been associated with transcriptional silencing of gene expression in mammalian cells [ 5 ]. Recent studies have demonstrated that epigenetic changes of cancer-related genes due to the methylation of gene promoter regions are early events in human carcinogenesis [ 6 – 7 ]. The human retinoic acid receptor beta2 (RARβ2) is a member of the nuclear receptor super-family and plays a key role in modulating the effects of retinoic acid (RA) on cell growth and differentiation [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Promoter Methylation of the Retinoic Acid Receptor Beta2 (RARβ2) Is Associated with Increased Risk of Breast Cancer: A PRISMA Compliant Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

BackgroundEpigenetic studies demonstrate that an association may exist between methylation of the retinoic acid receptor beta2 (RARβ2) gene promoter and breast cancer onset risk, tumor stage, and histological grade, however the results of these studies are not consistent. Hence, we performed this meta-analysis to ascertain a more comprehensive and accurate association.Materials and MethodsRelevant studies were retrieved from the PubMed, Embase and Chinese National Knowledge Infrastructure databases up to February 28, 2015. After two independent reviewers screened the studies and extracted the necessary data, meta-analysis was performed using Review Manager 5.2 software.ResultsNineteen eligible articles, including 20 studies, were included in our analysis. Compared to non-cancerous controls, the frequency of RARβ2 methylation was 7.27 times higher in patients with breast cancer (odds ratio (OR) = 7.27, 95% confidence interval (CI) = 3.01–17.52). Compared to late-stage RARβ2 methylated patients, the pooled OR of early-stage ones was 0.81 (OR = 0.81, 95% CI = 0.55–1.17). The OR of low-grade RARβ2 methylated patients was 0.96 (OR = 0.96, 95% CI = 0.74–1.25) compared to high-grade RARβ2 methylated patients.ConclusionRARβ2 methylation is significantly increased in breast cancer samples when compared to non-cancerous controls. RARβ2 could serve as a potential epigenetic marker for breast cancer detection and management.

show abstract

“…The applicability of cyclin D2 and RAR 2 methylated markers for the development of a breast tumor-screening assay showed mixed results [200]. Forty two per cent of the patients with primary diagnosis of breast fibroadenoma showed an aberrant methylation of at least one of tested genes in the circulating DNA though 33 % of patients with breast lesions not diagnosed as fibroadenoma (mastopathy) also displayed methylation.…”

Section: Breast and Ovarian Cancersmentioning

confidence: 95%

Biology of Circulating Nucleic Acids and Possible Roles in Diagnosis and Treatment in Diabetes and Cancer

Gahan

2012

IDDT

View full text Add to dashboard Cite

The presence of DNA and RNA circulating in human plasma and serum is described. The possible sources of the DNA/RNA in blood, their ability to enter other cells and to express in the recipient cells are discussed and the relationship with metastases considered. The possible role(s) of the DNA/RNA in clinical diagnosis, in monitoring treatment and in prognosis are considered for diabetes and oncology.

show abstract

Methylation‐Based Analysis of Circulating DNA for Breast Tumor Screening

Cited by 11 publications

References 10 publications

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Promoter Methylation of the Retinoic Acid Receptor Beta2 (RARβ2) Is Associated with Increased Risk of Breast Cancer: A PRISMA Compliant Meta-Analysis

Biology of Circulating Nucleic Acids and Possible Roles in Diagnosis and Treatment in Diabetes and Cancer

Contact Info

Product

Resources

About